Bakti G, Fisch H U, Karlaganis G, Minder C, Bircher J
Hepatology. 1987 Jul-Aug;7(4):629-38. doi: 10.1002/hep.1840070403.
Mechanisms responsible for disproportional sedation resulting from triazolam administration to patients with cirrhosis were investigated. Ordinary sedative doses (0.25 mg) were given p.o. to 8 cirrhotics and 18 controls. Plasma concentrations of unbound drug were assessed by capillary gas chromatography and equilibrium dialysis. Median apparent oral clearances of unbound triazolam were 14.8 ml per min per kg in cirrhotics and 23.9 ml per min per kg in controls (p less than 0.01). Clearances were significantly correlated with severity of liver disease as assessed by the aminopyrine breath test (Rs = 0.77, n = 17, p less than 0.001). At a time when plasma concentrations of unbound triazolam were the same in both groups, i.e., 2.25 hr after dosing, flicker sensitivity at 5 Hz which was used as an index of CNS performance was impaired by a factor of 3.2 in cirrhotics and 1.4 in controls (p less than 0.01 for group difference). Performance was also significantly lower in cirrhotics with the digit symbol substitution test (p less than 0.05). It is concluded that, in patients with cirrhosis, disproportional sedation after benzodiazepine administration may be due not only to impaired drug elimination, but also to hypersensitivity of the brain.
研究了三唑仑给药后肝硬化患者出现不成比例镇静作用的机制。将普通镇静剂量(0.25毫克)口服给予8名肝硬化患者和18名对照者。通过毛细管气相色谱法和平衡透析法评估血浆中游离药物的浓度。肝硬化患者游离三唑仑的中位表观口服清除率为每分钟每千克14.8毫升,对照者为每分钟每千克23.9毫升(p<0.01)。清除率与通过氨基比林呼气试验评估的肝病严重程度显著相关(Rs = 0.77,n = 17,p<0.001)。在两组游离三唑仑血浆浓度相同时,即给药后2.25小时,用作中枢神经系统功能指标的5赫兹闪烁敏感度在肝硬化患者中受损3.2倍,在对照者中受损1.4倍(组间差异p<0.01)。在数字符号替代试验中,肝硬化患者的表现也显著较低(p<0.05)。得出的结论是,在肝硬化患者中,苯二氮䓬类药物给药后不成比例的镇静作用可能不仅是由于药物消除受损,还由于大脑的高敏感性。